Newsletter · · Ashutosh Agarwal

Hims CEO Sees 50 Dollar GLP-1s and a China Supply Chain Chokehold - The Obesity-Drug Pipeline - Week of August 24, 2026

Obesity-drug newsletter for the week of August 24, 2026. Hims & Hers CEO Andrew Dudum says GLP-1s can reach 40 to 50 dollars a month, WuXi AppTech emerges as a China supply-chain chokehold, and new persistence data undercuts the volume bull case for Eli Lilly and Novo Nordisk.

The Obesity-Drug Pipeline

Week of August 24, 2026: Hims CEO Sees 50 Dollar GLP-1s and a China Supply Chain Chokehold

TL;DR (15 seconds)

  • The most influential voice in access this week put a shockingly low number on the table: GLP-1s at $40–50 a month. Andrew Dudum, CEO of Hims & Hers, said on CNBC that the drugs can be made and shipped to your door "for $40 to $50" and that the only thing keeping prices high is competition, not manufacturing. His timeline: today's $150–200 cash-pay prices drift to $99, then $79, and land at $40–50 by around 2030 when Wegovy's patent expires. If he's even directionally right, that's the net-price bear case arriving faster than anyone's model. Squawk Pod · On The Pen GLP-1 News

  • A Chinese company almost nobody has heard of turns out to sit under the entire GLP-1 supply chain, and Bloomberg now calls it "too big to ban." WuXi AppTech does the peptide manufacturing that Western drug companies outsource, and "however you get" a GLP-1, "it's probably originating in China." That's a supply-chain and geopolitical risk the market rarely prices, and the flip side of the case for building capacity at home. On The Pen GLP-1 News

  • The next-gen field got one more entrant with real Phase 3 data, and the number was only okay. A new investigational once-weekly shot, cervodotide, delivered about 12–13% weight loss at 76 weeks in a 725-patient Phase 3 trial published in the New England Journal of Medicine. Respectable, but well short of tirzepatide and retatrutide, a reminder the field is getting crowded with "good enough" drugs, which is exactly what compresses pricing. NEJM This Week

What's new

1. The $40–50 price call, from the person who arguably triggered the last price collapse. This was the single most thesis-relevant thing said all week, and it came from Andrew Dudum, CEO of Hims & Hers (OPERATOR/INSIDER) on Squawk Pod (August 18). Asked about the cost of GLP-1s, Dudum was blunt: "You can manufacture these medicines safely and get them to consumers safely, cold store shipped to your house overnight for $40 to $50." His key claim is that today's prices are a competition problem, not a cost problem, "it's only because of competitive dynamics that it doesn't exist today. It is not because of manufacturing constraints or supply chain issues."

He laid out an actual glide path: "As that marketplace expands, I think you'll see that $150 to $200 price point creep down to $99, creep down to $79. And I think probably by 2030, which is ultimately when semaglutide, Wegovy, around that time goes off patent... you'll see GLP-1s in the $40 to $50 a month range." His evidence is his own track record: Hims brought compounded GLP-1s to market "at $150, $200 price points per month" when "the drug companies were offering those at $1,500 per month", a drop of "almost 80, 90% in just 12 months."

Why take a telehealth CEO's price forecast seriously? Because he has skin in it and a track record of moving the actual market. The important caveat, flagged by the very next podcast (below): Dudum is not a neutral party, cheaper drugs are great for Hims. But he is also, demonstrably, one of the people who already forced brand prices down once.

"You can manufacture these medicines safely and get them to consumers safely, cold store shipped to your house overnight for $40 to $50.", Andrew Dudum, CEO of Hims & Hers, on Squawk Pod

2. The same $40–50 number, pressure-tested by a GLP-1 news host, plus the bull's escape hatch. On On The Pen GLP-1 News (August 18), host Dave Knapp (ANALYST/PUNDIT) built a whole episode around Dudum's number, and did the honest work of both taking it seriously and disclosing its bias. He reminded listeners where we came from: Hims launched compounded GLP-1s in 2024 at around $200/month when branded access "effectively was $1,000 a month," and "compounding changed what consumers believe these medications should cost." His line every PM should sit with: "once somebody has seen a version of something available for a couple hundred bucks, it's going to be really hard to convince them that they're going to go back and pay $1,000 for that medication."

But Knapp also surfaced the bull's counter, straight from the drugmakers' own playbook: volume replaces price. "We have both Lilly and Novo talking about making up for the lowering of prices of drugs by... expanding the volume." With "100 million people strong in the United States that could benefit," and the pill expanding the market further, "there is so much room for these pharmaceutical companies to grow. So the framework is already there where they're preparing investors like, yes, we're going to make less money on the script, but we're going to do more volumes to make up for that. And certainly Medicare rollout is part of that." That is the whole ballgame in one sentence: the bull needs volume to grow faster than price falls.

3. WuXi AppTech: the "China chokehold" almost nobody on the buy-side is watching. Also on On The Pen, Knapp walked through a Bloomberg story on WuXi AppTech, a name he correctly guessed most of his audience had never heard, and one that matters far more than its obscurity suggests. Bloomberg's framing, per Knapp: WuXi "may have become over this GLP boom too big to ban," and the phrase they used was the "GLP-1 chokehold."

His explanation of why is the useful part for the supply-chain read-through. Drug manufacturing isn't one factory; it's "raw materials... chemical intermediates... peptide fragments... peptide synthesis... manufacturing finish and fill injector devices, packaging", a chain with many suppliers across many countries. WuXi is "a very important participant in that pharmaceutical ecosystem, particularly when we're talking about peptides," and demand for peptide manufacturing "has absolutely exploded." His blunt bottom line: "however you get it, it's probably originating in China." That collides head-on with a US government that "has also spent years saying we're way too dependent on China for critical biotechnology." WuXi faces national-security scrutiny and disputes the government's characterization. The investable tension: this is both a risk (a single foreign choke point under the whole class) and a catalyst (every dollar of reshored capacity, Lilly has "invested billions and billions of dollars in infrastructure in the United States to make API, to make the pens", is a dollar WuXi's would-be Western competitors want).

4. A new competitor cleared Phase 3, with a merely decent number. On NEJM This Week (August 19), Dr. Lisa Johnson (ANALYST/PUNDIT), presenting the journal's papers, ran through Phase 3 data for cervodotide, an investigational once-weekly glucagon-receptor / GLP-1-receptor dual agonist. In a 725-patient trial of adults with obesity (BMI ≥30, or ≥27 with a complication) but without diabetes, mean weight change at week 76 was −12.2% on the 3.6 mg dose, −13% on the 6 mg dose, versus −5.4% on placebo, with the usual GI side effects (nausea, vomiting, diarrhea, constipation) more common than placebo.

For the competitive map, read the number, not the press release. A ~12–13% result over 76 weeks is real, but it lands below tirzepatide (Zepbound) and well below where retatrutide is tracking. The signal isn't "new threat to Lilly", it's "the field keeps filling up with good-but-not-great drugs." A crowded shelf of 12%-ish agents is precisely the condition under which Dudum's price-collapse thesis plays out: when several drugs are close enough, they compete on price.

5. Lilly's engine, quantified again, and a fast-food read-through. On DHUnplugged (August 19), the market-commentary hosts (ANALYST/PUNDIT) put fresh segment numbers on Lilly's franchise: Mounjaro (the diabetes label) hit $9.94 billion and Zepbound (the weight-loss label) $4.93 billion, with the wry-but-accurate observation that the two "are exactly... the same drug. One is, though, marketed for diabetes. One is marketed for weight loss." Lilly "raised their revenue guidance," and the hosts pegged it "definitely leading over Novo Nordisk."

The same episode gave the cleanest consumer read-through of the week: the hosts tied McDonald's soft sales partly to "a lot more people on peptides," calling GLP-1s "sort of a big aspect" of the pressure on fast food. Anecdotal, yes, but it's the same second-order trade (packaged food, QSR, impulse calories) that keeps showing up, now attached to a specific name.

6. The persistence problem got two hard numbers, and it's the bull case's quiet Achilles' heel. Two operators put startling figures on how many patients stop. On Squawk Pod, Dudum said that in the compounding era, "70% of patients after 30 or 90 days were not on the medication any longer", on drugs meant to be taken for years. And on Health Care Rounds (August 21), Wei-Li Shao, President of Omada Health (OPERATOR/INSIDER, a former Lilly executive whose company partners with Lilly), said pharma "lose[s] probably 60% of all of their patients... within 90 days of the first chronic prescription," and called GLP-1 "cycling on and off... the new yo-yo diet from the 80s and 90s. They're just doing it with drugs now."

Shao's other numbers matter for the "weight health vs. weight loss" debate the label-expansion bulls lean on. He cited a Wall Street Journal article covering "over 400,000 people retrospectively" that found "one in five of them actually were lacking significantly micro and macronutrients," because appetite fell but diet didn't improve. And he flagged muscle: "up to 35%, one third of the weight that you lose is actually of lean mass... most is it, is from muscle." Omada now has "well over 150,000 plus people... on GLP-1s" in a coaching program built to fix exactly these problems. His read on Lilly's own evolution is a genuine operator tell: the drugmaker's mindset is "shifting... from just prescriptions, market share, volume to understanding the contribution that their GLP-1 portfolio is having on human health," and he wants "deeper partnerships in the area of persistence and adherence." Translation for the book: every point of real-world discontinuation is revenue the Street's penetration models assume away.

The debate

The bull case (steel-manned): Volume eats price. Lilly just printed $9.94B of Mounjaro and $4.93B of Zepbound and raised guidance again, the leader is compounding faster than prices are falling, and management is openly telling investors the plan is "less money on the script, more volume." With ~100 million eligible Americans, an oral pill widening the funnel, and Medicare rollout ahead, penetration has years of runway. The new competitors keep landing below Lilly's efficacy (cervodotide at ~12–13%), so the leader's premium products hold their edge. And the supply-chain scare cuts the bull's way too: if the world is over-reliant on one Chinese manufacturer, the company pouring "billions and billions" into US capacity, Lilly, gets more valuable, not less.

The bear case (steel-manned): Follow the price. The CEO who already crushed brand prices once is telling you the floor is $40–50 a month, an 80–90% cut from where branded sat two years ago, and that only competition, not cost, is holding it up. A crowded field of "good enough" drugs (cervodotide the latest) guarantees that competition. Meanwhile the demand the bulls extrapolate is leakier than the models admit: 60–70% of patients are off within 90 days, one in five is malnourished, a third of lost weight is muscle, that's a churn machine, not an annuity. Layer on a supply chain that "too big to ban" WuXi controls, and you have a business whose price is falling, whose customers keep quitting, and whose factories sit in a geopolitical crossfire.

My read (a framing, not a call): Last week the debate was about who pays (employers pulling back). This week it moved to the more fundamental question of what it costs to make, and the honest answer, from the person best positioned to know, is "almost nothing." That reframes the entire thesis. If GLP-1s are structurally cheap to manufacture, then the long-run equity value doesn't live in the molecule, it lives in whoever controls demand, distribution, and adherence as price races toward marginal cost. That's why the two operators who dominated this week weren't drugmakers at all; they were an access platform (Hims) and an adherence platform (Omada). The single number that still resolves the bull/bear fight is net revenue per patient-year, held over time, price times persistence, and it's precisely the number the podcasts keep circling but never quite hand us cleanly.

Stocks in play

| Ticker | Bull case | Bear case | Next catalyst |

| --- | --- | --- | --- |

| Eli Lilly (LLY) | Franchise still compounding, Mounjaro $9.94B, Zepbound $4.93B, guidance raised again, clearly leading Novo; new rivals keep landing below its efficacy; investing "billions and billions" in US API/pen capacity as the reshoring winner. DHUnplugged · On The Pen | A credible operator sees cash-pay GLP-1s at $40–50/mo by ~2030; 60–70% of patients quit within 90 days; a crowding field (cervodotide) compresses pricing; retatrutide still under a biologic patent review with gray-market copies already circulating. Squawk Pod · Medical Millionaire | Retatrutide biologic/patent decision (carryover); further oral orforglipron roll-out; net revenue-per-script disclosure. |

| Novo Nordisk (NVO) | Still #2 with a huge installed base; its oral semaglutide is the incumbent pill; "was the original... Ozempic. Now has a pill." Semaglutide's ~2030 patent expiry is the reference point for the whole price-decline debate. DHUnplugged · Squawk Pod | Went essentially uncovered on its own merits for a second straight week, no CagriSema, UBT-251, or Capital Markets Day follow-up; the 2030 Wegovy patent cliff is now the anchor for the "$40–50" price-collapse case; same crowding and persistence problems hit Wegovy/Ozempic. | CagriSema / UBT-251 data; any pricing/volume commentary; patent-cliff planning. |

| Hims & Hers (HIMS) | CEO argues the whole system bends its way: cheap-to-make drugs plus a "closed-loop" data and adherence platform; owns a US peptide plant and at-home diagnostics; positioning to be the demand/distribution layer as price falls to marginal cost. Squawk Pod | An FTC investigation into how it marketed its "Wegovy pill knockoff"; forced off compounding as the regulatory tide turned; its own model relies on the same 70% early-discontinuation churn; talking its book on cheaper drugs. On The Pen · Squawk Pod | FTC investigation resolution; peptide (Category 1) reclassification; earnings follow-through on in-house AI care model. |

(This table covers the three names most substantively discussed this week, plus LLY and NVO per the mandate. Amgen's MariTide, Viking's VK2735, Pfizer/Metsera, Boehringer Ingelheim, WuXi AppTech, and McDonald's all surfaced by name, see Read-throughs.)

Read-throughs

  • Fast-followers (AMGN, VKTX, Roche): named only in passing. On On The Pen, Knapp rattled off the coming wave, "Boehringer Ingelheim... Viking Therapeutics, whether they partner with another company or not, Pfizer in their acquisition of [Metsera]... Amgen with MariTide. There's almost too many to name." On Squawk Pod, Dudum's competitor list echoed it: "companies like Kylera, you've got Viking Therapeutics, you've got new GLP-3 combos, you've got Chinese assets that will likely be acquired and moved domestically." No dedicated episode on any of them, and Roche's CT-388/CT-996 went unmentioned entirely again. The read: the pipeline names are now cited mainly as evidence of crowding, which is bearish for pricing across the board.

  • The new competitor to actually log: cervodotide. The week's one hard pipeline datapoint (see What's New #4), ~12–13% weight loss at 76 weeks, Phase 3, in NEJM This Week. Below the leaders on efficacy, but another shot on the shelf.

  • Contract manufacturing / fill-finish (CTLT, LNZA, TMO): finally relevant, via the WuXi story. After weeks of silence, the CDMO theme was loud this week, just through a Chinese name. The "too big to ban" WuXi AppTech story (On The Pen) is the clearest read-through the Western CDMOs have gotten in a month: if peptide-manufacturing dependence on China becomes a national-security fight, the onshoring beneficiaries are exactly Catalent, Lonza, Thermo Fisher and their peers. No US CDMO was named, but the setup for them has rarely been more explicit.

  • Pen / auto-injector suppliers (Ypsomed, Gerresheimer, Phillips Medisize): silent again. No supplier was named. The structural drift also continues against them: the growth story keeps tilting toward oral pills and toward manufacturing (API/peptide synthesis), not injection hardware.

  • Insurers / PBMs / employers (CVS, CI, UNH): quiet by name, but the employer-cost thread persists. No PBM was named this week. The one employer datapoint: Dudum, on Squawk Pod, relayed that Brian Moynihan told him Bank of America is "now spending $200+ million a year on GLP-1s for its employees," and noted small towns paying for police/fire/teachers "are not seeing, at least in the immediate sense, a payback." (Note: last week's issue cited BofA at "$250 million a year"; this week's figure, as Dudum quoted it, is "$200+ million", same story, slightly different number.) The employer-cost pressure that dominated last week is still there; it just wasn't the headline.

  • Compounding / 503A-503B / gray market: a genuinely useful regulatory deep-dive. On Medical Millionaire (August 19), Dr. Sean Arora (OPERATOR/INSIDER, who runs a clinic-compliance business) drew the line cleanly: tirzepatide can be compounded only as a 503A patient-specific product with a letter of medical necessity and an additive (e.g., B12, glycine), not as a 503B bulk multi-use vial, because Mounjaro is patented. Clinics buying bulk vials "will get in trouble" when the board of pharmacy shows up. On retatrutide he was emphatic: Eli Lilly holds the patent, it "hasn't even been really released yet... still completing its trials," it's under review "as a biologic," and it "should not be compounded", yet some 503A pharmacies quietly sell it and it's "being marketed on TikTok." His forensic tell: he no longer trusts the certificates of analysis on compounded retatrutide the way he does on semaglutide/tirzepatide. For the thesis: the gray market that caps brand pricing is still open, but the compliance noose is tightening, which is bullish for the branded incumbents' pricing power at the margin, and the reason Lilly's biologic gambit matters.

  • Medtech / bariatric: one intriguing, unconfirmable datapoint. On The Pen teased a company taking the opposite mechanistic bet, a GLP-1 antagonist (blocking GLP-1) aimed at post-bariatric-surgery hypoglycemia, whose stock "rose over 50% today alone" after Phase 3 data and the price it plans to charge. The episode didn't name the company in the portion captured, so I won't guess a ticker, but a +50% one-day move on a GLP-1-blocker is a reminder the incretin toolkit is branching in directions the "more receptors = better" narrative doesn't cover.

  • Food / QSR / consumer: McDonald's, by name. The clearest consumer read-through was DHUnplugged tying McDonald's soft sales partly to "a lot more people on peptides." Anecdotal, but a named stock this time.

What changed vs last week

Issue #4 (August 17) was about who pays, Starbucks dropping weight-loss coverage in October, GLP-1s hitting 11.4% of corporate drug claims, Lilly's oral orforglipron clearing the ACHIEVE-2 Phase 3 bar and winning UK approval, and the UK "200+ deaths" safety scare. Here's the drift into this week:

  • The debate moved from "who pays" to "what it costs to make." Last week's axis was payer/employer coverage. This week an operator (Dudum) reframed the whole thing around manufacturing cost near $40–50/month, a more fundamental, and more bearish-for-price, argument. This is an escalation of, not a repeat of, last week's cost-pressure theme.

  • New this week: the WuXi AppTech "China chokehold" supply-chain story (entirely new); cervodotide Phase 3 data (~12–13%, a new named competitor); the 503A/503B compounding mechanics deep-dive with retatrutide flagged as illegally compounded; hard persistence numbers (Omada: 60% off within 90 days; Hims: 70% off at 30–90 days) and the WSJ malnutrition finding (1 in 5 of 400,000+); and Lilly's segment split (Mounjaro $9.94B / Zepbound $4.93B).

  • Confirmed / extended: the discontinuation-and-durability theme from prior weeks got its hardest numbers yet; the compounding/gray-market channel remains wide open; Lilly's leadership over Novo restated with segment detail; the retatrutide biologic/patent question (last week's "Sept 24 Chicago appeal") reconfirmed as an active biologic review.

  • A number that moved: Bank of America's GLP-1 employer spend was cited last week at "$250 million a year" and this week (via Dudum quoting Moynihan) at "$200+ million a year." Same story, slightly different figure, worth noting, not over-reading.

  • Faded from last week: the Starbucks employer-coverage story got no follow-up; orforglipron's ACHIEVE-2 data and UK approval weren't revisited; the UK MHRA "deaths"/pancreatitis story went quiet; Lilly's counterfeit lawsuits and $3.8B vaccine acquisitions weren't mentioned; Andel's PBM-bypass pitch didn't recur; the HFpEF/SUMMIT clinical airing had no follow-on.

  • Still quiet (zero dedicated episodes): Novo Nordisk on its own merits (CagriSema, UBT-251, oral semaglutide strategy, Capital Markets Day), a second straight quiet week; Roche CT-388/CT-996; pen/auto-injector suppliers; label-expansion readouts (SELECT, SUMMIT, SURMOUNT-OSA, FLOW, STEP-HFpEF, ESSENCE, only a passing note that semaglutide 2.4 mg is FDA-approved for MASH, no new data); specific state legislation (e.g., Tennessee Fair Rx Act); and, still, clean TRx/NRx script counts with net price per script.

The honest summary: another light week for investor coverage, but a substantively important one. The conversation graduated from "will employers keep paying" to "these things are cheap to make and the field is crowding", which is the more durable version of the bear case, while the two loudest voices were access and adherence operators, not drugmakers. That, more than any single datapoint, is the tell about where the value is migrating.